Recent Updates
Recently added Catalysts

AZD9833 film-coated A Dose 1

Phase 1

Undisclosed | Small molecule | Other |AstraZeneca PLC|Trials Updated: Jan 20, 2021

AZD9833 film-coated A Dose 1 target and mechanism

ModalitySmall molecule

Also known as AZD9833 film-coated tablet A Dose 1

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

AZD9833 film-coated A Dose 1 clinical trials

AZD9833 film-coated A Dose 1 · 1 trial · 1 indication

Phase 1 1
NCT04546347A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833Healthy Volunteers
COMPLETED32 Analytics
PHASE1COMPLETED
A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833
Healthy Volunteers
NCT0454634732
Unlock trial analytics

Study Endpoints

Primary Endpoints

Relative bioavailability of AZD9833 based on Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)
Collection of plasma samples from pre-dose to 72 hours post-dose

Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on AUC0-t

Relative bioavailability of AZD9833 based on area under the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf)
Collection of plasma samples from pre-dose to 72 hours post-dose

Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on AUC0-inf

Relative bioavailability of AZD9833 based on Maximum observed concentration (Cmax)
Collection of plasma samples from pre-dose to 72 hours post-dose

Assessment of the PK (pharmacokinetics) on AZD9833 by measuring relative bioavailability based on Cmax

Secondary Endpoints

Area under the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf) for AZD9833 vs [14C]-AZD9833 and total radioactivity
Collection of plasma samples from pre-dose to 72 hours post-dose
Number of adverse events (AE) experienced by subjects
AEs recorded from the time of informed consent until discharge from the study (72 hours post-dose)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
14CAZD9833 Infusion NMT 22.8 kBq/5mLEXPERIMENTALDose 1 14CAZD9833 Solution for Infusion
AZD9833 film-coated tablet A Dose 1EXPERIMENTALDose 1 AZD9833 film-coated tablet type A
AZD9833 Oral SolutionEXPERIMENTALDose 1 AZD9833 oral solution
AZD9833 film-coated tablet B Dose 1EXPERIMENTALDose 1 AZD9833 film-coated tablet type B
AZD9833 film-coated tablet A Dose 2EXPERIMENTALDose 2 AZD9833 film-coated tablet type A
AZD9833 film-coated tablet B Dose 2EXPERIMENTALDose 2 AZD9833 film-coated tablet type B

Interventions

NameTypeDescription
[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)RADIATIONDose of \[14C\]AZD9833 Solution for Infusion
AZD9833 film-coated tablet A Dose 1DRUGDose 1 AZD9833 film-coated tablet A Dose 1
AZD9833 Oral SolutionDRUGAZD9833 Oral Solution
AZD9833 film-coated tablet B Dose 1DRUGAZD9833 film-coated tablet B Dose 1
AZD9833 film-coated tablet A Dose 2DRUGDose 1 of AZD9833 film-coated tablet A Dose 2
AZD9833 film-coated tablet B Dose 2DRUGDose 1 of film-coated tablet B Dose 2
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 70 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy post-menopausal females, defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the post menopausal range. Subjects taking prescribed medications are permitted on a case by case basis, as long a...

Countries:United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about AZD9833 film-coated A Dose 1

What is AZD9833 film-coated A Dose 1?

AZD9833 film-coated A Dose 1 is a small molecule drug candidate developed by AstraZeneca PLC. It is an investigational agent that has been studied in a Phase 1 clinical trial in healthy female volunteers. The specific therapeutic indication for this drug candidate has not been disclosed.

Who is developing AZD9833 film-coated A Dose 1?

AZD9833 film-coated A Dose 1 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this small molecule drug candidate.

What phase is AZD9833 film-coated A Dose 1 in?

AZD9833 film-coated A Dose 1 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA.

What clinical trials is AZD9833 film-coated A Dose 1 in?

AZD9833 film-coated A Dose 1 has been evaluated in one completed Phase 1 trial, NCT04546347, titled A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833. The trial enrolled 32 healthy female volunteers in the United Kingdom.

Is AZD9833 film-coated A Dose 1 the same as AZD9833 film-coated tablet A Dose 1?

Yes, AZD9833 film-coated A Dose 1 is also known as AZD9833 film-coated tablet A Dose 1. Both names refer to the same small molecule drug candidate developed by AstraZeneca PLC under the AZD9833 program.

Explore more on BiopharmaWatch

AstraZeneca PLC (AZN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track